500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Material disclosure
Solid Biosciences Inc. Enters $84 Million Securities Purchase Agreement
Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions
News
News, Legal Opinion
Annual Report to Security Holders
Other Events
Investor Presentation
FY 2025
Q3
Q2
Q1
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload